Barry D. Bertolet, M.D., FACC
Principal Investigator
CHAMPION
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects who Require Percutaneous Coronary Intervention
Summary: The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring percutaneous coronary intervention (PCI) measured by a composite of all-cause mortality, myocardial infarction and ischemia-driven revascularization.